Abstract: Objective To explore the clinical curative effect of concurrent radiochemotherapy on intermediate-stage and advanced cervical cancer and factors influencing its prognosis. Methods A retrospective investigation was performed on clinical data about 125 cervical cancer patients who underwent concurrent radiochemotherapy alone from 2005 to 2010 in Nanjing Drum Tower Hospital, and the curative effect of concurrent radiochemotherapy on intermediate-stage and advanced cervical cancer and its influence on prognosis were analyzed. Results The average age of 125 patients was(46.48±10.86) years.Of the 125 cases, there were 55 cases in stage Ⅱ, 47 cases in stageⅢ, and 23 cases in stageⅣ, with 110 cases of squamous cell carcinomas and 15 cases of adenocarcinoma.The three-year and five-year survival rates of patients were 72.00% and 61.60%, respectively.Univariate analysis results showed that the survival rates were significantly related to age, degree of differentiation, FIGO staging, tumor diameter and quantity of hemoglobin(P< 0.05) and moreover, the five-year survival rate was significantly related to histological classification(P< 0.05).Multivariate analysis showed that the degree of differentiation and FIGO staging(P=0.00) were independent prognostic factors that influenced three-year and five-year survival rates of patients.Of the 125 cases, radiation enteritis occurred in 77 cases(61.60%), irradiation cystitis in 8 cases(6.40%), lower limb lymph nodule swelling in 6 cases(4.80%), 114 cases(91.20%) showed different degrees of bone marrow suppression, vulvitis occurred in all cases(100%) and 119 cases(95.2%) showed different degrees of digestive tract symptoms.Univariate analysis indicated that the occurrence of concurrent radiochemotherapy complications had no significant relevance with age, histological classification, differentiation degree, tumor size, FIGO staging and hemoglobin amount. Conclusion The prognosis of intermediate-stage and advanced cervical cancer treated by concurrent radiochemotherapy has relevance with patients' age, histological classification, differentiation degree, tumor size, FIGO staging and hemoglobin amount.